FREMONT, Calif., April 10 /PRNewswire-FirstCall/ -- Vermillion, Inc.
(Nasdaq: VRML), a molecular diagnostics company, today announced the
appointment of John F. Hamilton to its board of directors. Mr. Hamilton is
the former vice president and chief financial officer of Depomed, Inc., a
specialty pharmaceutical company.
"John brings more than 20 years of active board-level engagement on
financial, strategic and audit matters to Vermillion. His solid experience
working with small to mid-size companies in the healthcare sector is a perfect
fit with our business model," said Gail Page, President and CEO of Vermillion.
"We are pleased to welcome John to the board, especially at such an exciting
time in the company's evolution as we prepare to commercialize several of our
diagnostic tests later this year. His financial savvy and analytical approach
will prove invaluable to the Company."
Mr. Hamilton began his career in the banking industry and went on to hold
senior financial positions at several biopharmaceutical companies including
Glyko, Inc. -- now BioMarin Pharmaceuticals -- and Chiron Corporation. He
sits on the regional board of directors of the Association of Bioscience
Financial Officers and is past-president of the Treasurers Club of San
Francisco. Mr. Hamilton received his M.B.A. from the University of Chicago
and his B.A. in International Relations from the University of Pennsylvania.
Mr. Hamilton's appointment to Vermillion's board of directors went into
effect on April 9, 2008. Additionally, Mr. Hamilton will serve as chairman of
the Company's audit committee. He will replace Judy Bruner, executive vice
president of administration and chief financial officer of SanDisk
Corporation, who resigned from the board of directors on April 8, 2008.
"We would like to thank Judy for her leadership, expertise and
contributions as a board member," said Page. "She has added significant value
to Vermillion for the past 5 years and we wish her well in her future
Vermillion, Inc. is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with its
prestigious scientific collaborators, has diagnostic programs in oncology,
hematology, cardiology and women's health. Vermillion is based in Fremont,
California. Additional information about Vermillion can be found on the Web at
Forward Looking Statement:
This news release contains forward-looking statements that involve
significant risks and uncertainties, including statements regarding
Vermillion's plans, objectives, expectations and intentions and the risks and
uncertainties discussed in Vermillion's latest Form 10-K and Vermillion's
periodic reports on Form 10-Q and Form 8-K. These forward-looking statements
are based on Vermillion's current expectations. Vermillion is providing this
information as of the date of this news release and does not undertake any
obligation to update any forward-looking statements as a result of new
information, future events or otherwise. Forward-looking statements cannot be
guaranteed and actual results may differ materially from Vermillion's current
expectations. You are encouraged to read Vermillion's reports filed with the
U.S. Securities and Exchange Commission, available at http://www.sec.gov.
SOURCE Vermillion, Inc.
Investors, Sue Carruthers of Vermillion, Inc.,
Media, Daryl Messinger of WeissComm Partners,
+1-415-946-1062, for Vermillion, Inc.
Web site: http://www.vermillion.com